Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

CEO

ISIN

US9840156023

Listings

0 Comments

Share your thoughts

FAQ

What is Xenetic Biosciences stock price today?▼

The current price of XBIO.BOATS is $3.13 USD — it has increased by +1.29% in the past 24 hours. Watch Xenetic Biosciences stock price performance more closely on the chart.

What is Xenetic Biosciences stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Xenetic Biosciences stocks are traded under the ticker XBIO.BOATS.

What is Xenetic Biosciences market cap?▼

Today Xenetic Biosciences has the market capitalization of 7.17M

When is the next Xenetic Biosciences earnings date?▼

Xenetic Biosciences is going to release the next earnings report on May 07, 2026.

What is Xenetic Biosciences revenue for the last year?▼

Xenetic Biosciences revenue for the last year amounts to 5M USD.

What is Xenetic Biosciences net income for the last year?▼

XBIO.BOATS net income for the last year is -7.92M USD.

In which sector is Xenetic Biosciences located?▼

Xenetic Biosciences operates in the Other sector.

When did Xenetic Biosciences complete a stock split?▼

Xenetic Biosciences has not had any recent stock splits.